Abhijit Bhattacharya: Yes. So, let me start first with the book-to-bill. It was about 1.14, so again, more bookings and billings. The overall cancellation impact is about slightly more than 8%. So, if you take out the impact of the cancellation as well as the normalization due to COVID, because in the Connected Care segment, you see the 10% decline, and that’s principally because of the COVID demand that came in last year. So — the impact of both of these put together is more than the 8%. So, it would be roughly a kind of 1% growth. I think we have a lot of questions on the order book, and I’d like to clarify what we also showed on the slides earlier, that we start the year with a very, very good coverage for sales in 2023.
You’ve seen in MR, we have 30% higher coverage in IGT and patient monitoring, and we didn’t have it on the slide. But also in Ultrasound, we have more than 20% better coverage. So, the coverage for this year is actually in a very good space. Then, coming to your question on the SRC assumption, you kind of had answered the question a bit. Till we know the outcome of the consent decree, putting a year-by-year guidance becomes a bit premature. So, I think as Roy mentioned at the start, we are assuming a low single-digit growth this year, and then we will come with more clear guidance on the intermittent years as we have clarity around the consent decree.
Ed Ridley-Day: Thank you, Abhijit, for that. And just a quick follow-up on the capital allocation. You highlighted, obviously, some thought around the buyback. Can you confirm whether you’re going to go ahead with that? Or when might we hear some further thoughts on the buyback commitment, obviously, considering the broad cash demand that you have this year?
Abhijit Bhattacharya: Yes. So, the existing buyback, we have, as you know, executed in the — through forward. So, those will get due this year, and we will execute on that. So, there is no change in the commitment there. So that’s basically where we stand on that.
Ed Ridley-Day: Fair enough. Thank you.
Abhijit Bhattacharya: Thanks, Ed.
Operator: Thank you. We will now take our next question. And your next question comes from the line of Robert Davies from Morgan Stanley. Please go ahead. Your line is open.
Robert Davies: Yes. Thanks for taking my questions. My first one was just on, I think, your bridge you had for 2022 to 2025. So, you had in amongst — I think it was pricing mix in COGS of 4% to 5% increase. Just be curious there, how much of that is underpinned by what you can see in your current order backlog versus what you’re intending to put through effectively in your book-to-bill part of your business? And then, my second question was just around the Personal Health, just around the consumer outlook there. But just curious in terms of what you’re seeing in — I know you mentioned sort of more difficult comp moving into the first quarter, but just on an underlying basis, just be curious to see how customer behavior is sort of feeding into growth trends there through the early part of the year.
And then, on the last one, was just around the sort of post 2025 outlook. So, you put sort of mid- to high-teens. In simple terms, how do you get there? I mean that’s obviously well above anything Philips has done before. And I think probably, if anything, the margin targets have always been a bit more stretched than the growth targets for Philips. What would need to change really between now and ’25 to turn this into a mid- to high-teens margin business? Thank you.
Abhijit Bhattacharya: Should I start with the first one, then you…
Roy Jakobs: Yes.
